slotkoers
Andere beurzen
|
||
- CAD | - |
15/05 | Transcript : MediPharm Labs Corp., Q1 2024 Earnings Call, May 15, 2024 | |
15/05 | MediPharm Labs Q1 Brutowinst, Stijging | MT |
Omzet 2024 * | 42 mln. 30,8 mln. 28,42 mln. | Omzet 2025 * | 54,91 mln. 40,27 mln. 37,16 mln. | Marktkapitalisatie | 32,32 mln. 23,7 mln. 21,87 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -9 mln. -6,6 mln. -6,09 mln. | Nettowinst (verlies) 2025 * | -2 mln. -1,47 mln. -1,35 mln. | EV/omzet 2024 * | 0,77 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 0,59 x |
K/w-verhouding 2024 * |
-4
x | K/w-verhouding 2025 * |
-16
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,53% |
Recentste transcriptie over Medipharm Labs Corp
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Pidduck
CEO | Chief Executive Officer | - | 20-04-22 |
Greg Hunter
DFI | Director of Finance/CFO | - | 08-02-21 |
Keith Strachan
PSD | President | - | 01-10-18 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Michael Bumby
BRD | Director/Board Member | 60 | 01-04-23 |
David Pidduck
CEO | Chief Executive Officer | - | 20-04-22 |
Shelley Martin
BRD | Director/Board Member | - | 22-06-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+37,29% | 6,02 mld. | |
-21,28% | 4,19 mld. | |
+4,52% | 3,25 mld. | |
-18,16% | 2,87 mld. | |
-7,70% | 2,37 mld. | |
+41,50% | 1,89 mld. | |
-4,05% | 1,58 mld. | |
-15,56% | 1,54 mld. | |
-14,62% | 1,5 mld. |
- Beurs
- Aandelen
- Koers LABS
- Koers